SCHEMBL1665568

SCHEMBL1665568

NC(=O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.57
CA2 P00918 4/20 0.57
MMP1 P03956 1/20 0.57
MMP2 P08253 1/20 0.57
MMP9 P14780 1/20 0.57
MMP8 P22894 1/20 0.57
MMP13 P45452 1/20 0.57
F2 P00734 1/20 0.56
PRSS1 P07477 1/20 0.56
PRSS2 P07478 1/20 0.56
PRSS3 P35030 1/20 0.56
CYP19A1 P11511 1/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
CRHBP P24387 1/20 0.53
CRHR2 Q13324 1/20 0.53
CA12 O43570 1/20 0.53
CA3 P07451 1/20 0.53
CA4 P22748 1/20 0.53
CA6 P23280 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1242066 0.85 MMP1 (0.61) CA1CA2MMP1MMP2MMP9
SCHEMBL6361411 0.84 KMT2A (0.69) CA1CA2MMP1MMP2MMP9
SCHEMBL22492554 0.81 GAA (0.66) CA1CA2MMP1MMP2MMP9
SCHEMBL13723973 0.80 CA1 (0.65) CA1CA2MMP1MMP2MMP9
SCHEMBL7526085 0.79 CA2 (0.63) CA1CA2MMP1MMP2MMP9
SCHEMBL11004638 0.78 CA2 (0.62) CA1CA2MMP1MMP2MMP9
SCHEMBL4859251 0.78 ALDH1A1 (0.61) CA1CA2MMP1MMP2MMP9
SCHEMBL20743688 0.78 MMP1 (0.66) CA1CA2MMP1MMP2MMP9
SCHEMBL6850445 0.78 MEP1B (0.62) CA1CA2MMP1MMP2MMP9
SCHEMBL6850069 0.78 MEP1B (0.62) CA1CA2MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011050284-A1 PYRAZOLYLPYRIDINE ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2011-04-28 WO disclosed
US-6774212-B2 FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-08-10 US disclosed